Okay, we reported first quarter revenues of $13.8 million, up 26% on both the reported and constant currency basis. These results encourage us that our strategy to drive top line growth through our direct sales business on a global basis is firmly working. Specifically, direct sales rose strongly up 45% including Laprolan and up 15% excluding Laprolan.Total reported sales growth was tempered by 20% decline in private label sales, which as we have noted in the past is a business that fluctuates from quarter to quarter as was the case this quarter. Importantly, we posted 27% and 18% growth respectively in our direct sales businesses in the U.S. and the UK while Laprolan, which we acquired in April 2011, grew modestly from the prior quarter and continues to be a promising addition to our international direct sales business. And Dave will provide more detail on the revenue performance in just a minute.
Rochester Medical CEO Discusses F1Q2012 Results - Earnings Call Transcript
Check Out Our Best Services for Investors
- $2.5+ million portfolio
- Large-cap and dividend focus
- Intraday trade alerts from Cramer
Access the tool that DOMINATES the Russell 2000 and the S&P 500.
- Buy, hold, or sell recommendations for over 4,300 stocks
- Unlimited research reports on your favorite stocks
- A custom stock screener
- Model portfolio
- Stocks trading below $10
- Intraday trade alerts
Every recommendation goes through 3 layers of intense scrutinyquantitative, fundamental and technical analysisto maximize profit potential and minimize risk.
Our options trading pros provide over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.